ArticleCardio-oncology (London, England)2022

Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis.

Jiandong Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.